4
Changes in Ownership
Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001992260-26-000006
EVP, Head of R&D sold 26,530 shares at an average $90.62 ($2,404,077)
- EVP, Head of R&D acquired 26,530 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Randhawa Simrat EVP, Head of R&D | 2026-06-01 | Option exercise 10b5-1 | +3,998 | $8.44 | $33,743 | 7,998 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-06-01 | Option exercise 10b5-1 | +6,908 | $17.88 | $123,515 | 14,906 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-06-01 | Option exercise 10b5-1 | +6,249 | $21.77 | $136,041 | 21,155 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-06-01 | Option exercise 10b5-1 | +9,375 | $22.07 | $206,906 | 30,530 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-06-01 | Sale 10b5-1 | −5,428 | $89.72 | $487,000 | 25,102 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-06-01 | Sale 10b5-1 | −16,943 | $90.72 | $1,537,069 | 8,159 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-06-01 | Sale 10b5-1 | −4,159 | $91.37 | $380,008 | 4,000 | D |
| Derivatives | |||||||
| Randhawa Simrat EVP, Head of R&D | 2026-06-01 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,998 | 0 | D | ||
| Randhawa Simrat EVP, Head of R&D | 2026-06-01 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,908 | 64,276 | D | ||
| Randhawa Simrat EVP, Head of R&D | 2026-06-01 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,249 | 47,925 | D | ||
| Randhawa Simrat EVP, Head of R&D | 2026-06-01 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,375 | 96,875 | D | ||
| Open-market sales · 26,530 sh · avg $90.62 · $2,404,077 | |||||||
Loading xslF345X06/ownership.xml…